Chronic lymphocytic leukemia: a clinical review including Korean cohorts
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Only 5th decade ago, chronic lymphocytic leukemia (CLL) was only recognized as disease group of presenting features like peripheral lymphocytosis, organomegaly including of splenomegaly. As understanding of disease biology and molecular diagnostic tools are getting improved gradually, characterization of variation in CLL’s clinical courses was facilitated, resulting in better risk stratification and targeted treatments. Consequently multiple new targeted agents have been used in treatment of CLL, it makes improved clinical outcome. Rituximab containing chemoimmunotherapy (combination of rituximab, f ludarabine, and cyclophosphamide) have shown better overall response rate and progression-free survival on fit patients’ group in front-line setting, result in standard first-line therapeutic option for CLL. Furthermore, after introducing that the B-cell receptor is crucial for the evolution and progression of CLL, emerging treatments targeting highly activated surface antigens and oncogenic signaling pathways have been associated with several successes in recent decades. These include new anti-CD 20 monoclonal antibody (obinutuzumab), the bruton tyrosine kinase inhibitor (ibrutinib), the phosphatidylinositol 3-kinase inhibitor (idelalisib), and B-cell CLL/lymphoma 2 inhibitor (ABT-199 and ABT-263). So, we discuss not only general pathophysiology of CLL, but also rapidly advancing treatment strategies that are being studied or approved for treatment of CLL.
Abstract
Only 5th decade ago, chronic lymphocytic leukemia (CLL) was only recognized as disease group of presenting features like peripheral lymphocytosis, organomegaly including of splenomegaly. As understanding of disease biology and molecular diagnostic tools are getting improved gradually, characterization of variation in CLL’s clinical courses was facilitated, resulting in better risk stratification and targeted treatments. Consequently multiple new targeted agents have been used in treatment of CLL, it makes improved clinical outcome. Rituximab containing chemoimmunotherapy (combination of rituximab, f ludarabine, and cyclophosphamide) have shown better overall response rate and progression-free survival on fit patients’ group in front-line setting, result in standard first-line therapeutic option for CLL. Furthermore, after introducing that the B-cell receptor is crucial for the evolution and progression of CLL, emerging treatments targeting highly activated surface antigens and oncogenic signaling pathways have been associated with several successes in recent decades. These include new anti-CD 20 monoclonal antibody (obinutuzumab), the bruton tyrosine kinase inhibitor (ibrutinib), the phosphatidylinositol 3-kinase inhibitor (idelalisib), and B-cell CLL/lymphoma 2 inhibitor (ABT-199 and ABT-263). So, we discuss not only general pathophysiology of CLL, but also rapidly advancing treatment strategies that are being studied or approved for treatment of CLL.
참고문헌 (54)
- Dores GM, "Chronic lymphocytic leukaemia and small lymphocytic lymphoma:overview of the descriptive epidemiology", Br J Haematol, 139, pp.809~819 (2007)
- Zenz T, "From pathogenesis to treatment of chronic lymphocytic leukaemia", Nat Rev Cancer, 10, pp.37~50 (2010)
- Damle RN, "Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia", Blood, 94, pp.1840~1847 (1999)
- Rassenti LZ, "Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia", Blood, 112, pp.1923~1930 (2008)
- Kuppers R, "Cellular origin of human B-cell lymphomas", N Engl J Med, 341, pp.1520~1529 (1999)
- Forconi F, "The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL", Blood, 115, pp.71~77 (2010)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010", Cancer Research and Treatment, 45(1), pp.1~14 (2013), 대한암학회[DOI]
- Jang MA, "Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior", Int J Hematol, 97, pp.403~408 (2013)
- Yoon JH, "Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence", Hematol Oncol, 32, pp.169~177 (2014)
- Dohner H, "Genomic aberrations and survival in chronic lymphocytic leukemia", N Engl J Med, 343, pp.1910~1916 (2000)
- Zelenetz AD, "Non-Hodgkin’s lymphomas, version 4.2014", J Natl Compr Canc Netw, 12, pp.1282~1303 (2014)
- Oscier D, "Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation", Haematologica, 95, pp.1705~1712 (2010)
- Haferlach C, "Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping", Leukemia, 21, pp.2442~2451 (2007)
- Grever MR, "Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia:results from the US Intergroup Phase III Trial E2997", J Clin Oncol, 25, pp.799~804 (2007)
- Chena C, "Interphase cytogenetic analysis in Argentinean B-cell chronic lymphocytic leukemia patients: association of trisomy 12 and del(13q14)", Cancer Genet Cytogenet, 146, pp.154~160 (2003)
- Arif M, "Independent clones of trisomy 12 and retinoblastoma gene deletion in Japanese B cell chronic lymphocytic leukemia, detected by fluorescence in situ hybridization", Leukemia, 9, pp.1822~1827 (1995)
- Dong HJ, "The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)", Ann Hematol, 90, pp.709~717 (2011)
- Wu SJ, "Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence: clinical implication and comparison between the West and the East", Ann Hematol, 92, pp.799~806 (2013)
- Hallek M, "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines", Blood, 111, pp.5446~5456 (2008)
- Rawstron AC, "Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia", N Engl J Med, 359, pp.575~583 (2008)
- Rawstron AC, "International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia", Leukemia, 21, pp.956~964 (2007)
- DiRaimondo F, "The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease", Cancer, 94, pp.1721~1730 (2002)
- Binet JL, "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis", Cancer, 48, pp.198~206 (1981)
- Rai KR, "Clinical staging of chronic lymphocytic leukemia", Blood, 46, pp.219~234 (1975)
- Rossi D, "Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia", Blood, 121, pp.1403~1412 (2013)
- CLL Trialists’ Collaborative Group, "Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials", J Natl Cancer Inst, 91, pp.861~868 (1999)
- The French Cooperative Group on Chronic Lymphocytic Leukemia, "Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients", Blood, 75, pp.1414~1421 (1990)
- Wierda WG, "Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia", Blood, 117, pp.6450~6458 (2011)
- Tam CS, "Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma", Cancer, 106, pp.2412~2420 (2006)
- Foon KA, "Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia", J Clin Oncol, 27, pp.498~503 (2009)
- Byrd JC, "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia:results from Cancer and Leukemia Group B 9712(CALGB 9712)", Blood, 101, pp.6~14 (2003)
- Hillmen P, "Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study", J Clin Oncol, 32, pp.1236~1241 (2014)
- Pettitt AR, "Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial", J Clin Oncol, 30, pp.1647~1655 (2012)
- Hillmen P, "Using the biology of chronic lymphocytic leukemia to choose treatment", Hematology Am Soc Hematol Educ Program, 2011, pp.104~109 (2011)
- Keating MJ, "Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia", Blood, 114, pp.2381~ (2009)
- Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
- O’Brien S, "Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia", J Clin Oncol, 25, pp.1114~1120 (2007)
- Byrd JC, "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia", Blood, 123, pp.1302~1308 (2014)
- Burger JA, "Safety and activity of ibrutinib plus rituximab for patients with highrisk chronic lymphocytic leukaemia: a single-arm, phase 2 study", Lancet Oncol, 15, pp.1090~1099 (2014)
- Byrd JC, "Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia", N Engl J Med, 369, pp.32~42 (2013)
- Furman RR, "Idelalisib and rituximab in relapsed chronic lymphocytic leukemia", N Engl J Med, 370, pp.997~1007 (2014)
- Green DR, "Apoptosis therapy: driving cancers down the road to ruin", Nat Med, 19, pp.131~133 (2013)
- Goede V, "Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions", N Engl J Med, 370, pp.1101~1110 (2014)
- Mertens D, "Prognostic and predictive factors in patients with chronic lymphocytic leukemia:relevant in the era of novel treatment approaches?", J Clin Oncol, 32, pp.869~872 (2014)
- Brown JR, "The treatment of relapsed refractory chronic lymphocytic leukemia", Hematology Am Soc Hematol Educ Program, 2011, pp.110~118 (2011)
- Porter DL, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", N Engl J Med, 365, pp.725~733 (2011)
- Chapel H, "Immunoglobulin replacement in patients with chronic lymphocytic leukaemia:a comparison of two dose regimes", Br J Haematol, 88, pp.209~212 (1994)
- Rossi D, "Richter syndrome: molecular insights and clinical perspectives", Hematol Oncol, 27, pp.1~10 (2009)
- Parikh SA, "Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients", Br J Haematol, 162, pp.774~782 (2013)
- Chigrinova E, "Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome", Blood, 122, pp.2673~2682 (2013)
- Tsimberidou AM, "Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation", J Clin Oncol, 24, pp.2343~2351 (2006)
- Borthakur G, "Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab: incidence and predictors", Br J Haematol, 136, pp.800~805 (2007)
- Dearden C, "The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia", Blood, 111, pp.1820~1826 (2008)
- Moreno C, "Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance", Blood, 116, pp.4771~4776 (2010)